Cantargia publishes interim report for first quarter 2019
Cantargia AB’s (”Cantargia”) interim report for first quarter 2019 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the first quarter · In January 2019, the first patient initiated treatment with Cantargia’s CAN04 antibody in the phase IIa stage of the CANFOUR study. · In March 2019, Cantargia completed a directed share issue of approximately SEK 106 million to fund expanded clinical development of CAN04. Significant events after the end of the period · In April 2019, Cantargia AB announced that phase I